Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | President & CCO | April 13, 2023 | April 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HERON THERAPEUTICS, INC. /DE/
Report date April 13, 2023 · Filed April 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,648 |
Ending reported balance
After 2023-04-13 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-04-13 · Exercise / conversion · Acquired 1,250 · Balance 44,096 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2023-04-13 · Exercise / conversion · Acquired 4,564 · Balance 48,660 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 3 · 2023-04-13 · Tax withholding · Disposed 2,012 · Balance 46,648 F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,500 |
Reported balance
After 2023-04-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-04-13 · Exercise / conversion · Disposed 1,250 · Balance 7,500 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 27,936 |
Reported balance
After 2023-04-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-04-13 · Exercise / conversion · Disposed 4,564 · Balance 27,936 F1: Restricted stock units convert into common stock on a one-for-one basis. F4: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021). |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
F3: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
F4: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SENOMYX INC
Report date November 02, 2018 · Filed November 02, 2018
Section 16 reporting ended · disclosed 2018-11-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-11-02 · Other · Disposed 111,469 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: Prior reports erroneously reflected all shares as indirectly held by trust, when a portion of the shares were actually directly held by the insider as reflected herein. |
| Common StockSEC Table I · non-derivative | IndirectBy family trust | 0 |
Reported balance
After 2018-11-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-11-02 · Other · Disposed 108,293 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F4: Includes 25,772 shares of Common Stock that were acquired by the Reporting Person on 8/31/18 pursuant to the Issuer's Employee Stock Purchase Plan. F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: Prior reports erroneously reflected all shares as indirectly held by trust, when a portion of the shares were actually directly held by the insider as reflected herein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2027-03-14 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-11-02 · Disposition to issuer · Disposed 417,000 · Balance 0 F5: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2028-03-14 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-11-02 · Disposition to issuer · Disposed 363,000 · Balance 0 F5: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").
F3: Prior reports erroneously reflected all shares as indirectly held by trust, when a portion of the shares were actually directly held by the insider as reflected herein.
F4: Includes 25,772 shares of Common Stock that were acquired by the Reporting Person on 8/31/18 pursuant to the Issuer's Employee Stock Purchase Plan.
F5: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2020 Filed Oct 15, 2020 20:24 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $15.72 | $0.00 |
DisclosureSEC source: 0001209191-20-054908 · doc4.xml · derivative · entry 1 POYHONEN JOHN · CIK 0001286100 · President & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2030-10-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 21:29 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 55,562 | $0.00 Strike: $25.02 | $0.00 |
DisclosureSEC source: 0001209191-19-061796 · doc4.xml · derivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,562 Underlying: Common Stock · 55,562 shares Expires 2029-12-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| October 03, 2019 Filed Oct 4, 2019 23:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | PurchaseCommon Stock | 5,143 | $17.50 | $90,002.50 |
DisclosureSEC source: 0001209191-19-052611 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,143 Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 12:48 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $18.29 | $0.00 |
DisclosureSEC source: 0001209191-19-042303 · doc4.xml · derivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-07-15 F1 · derivative.exercise_date: Options shall vest and become exercisable with respect to 75,000 shares on the first anniversary of his first day of employment (the "Grant Date"), followed by 225,000 shares vesting ratably each month over the subsequent three years, such that 300,000 options will be fully vested on the four year anniversary of the Grant Date. Read SEC document |
| May 22, 2019 Filed May 23, 2019 12:39 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | PurchaseCommon Stock | 3,000 | $17.55 | $52,650.00 |
DisclosureSEC source: 0001209191-19-032198 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| December 15, 2018 Filed Dec 19, 2018 01:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $24.97 | $0.00 |
DisclosureSEC source: 0001209191-18-063347 · doc4.xml · derivative · entry 2 POYHONEN JOHN · CIK 0001286100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-12-15 Read SEC document |
| December 15, 2018 Filed Dec 19, 2018 01:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $24.97 | $0.00 |
DisclosureSEC source: 0001209191-18-063347 · doc4.xml · derivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2028-12-15 F1 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:12 UTC | SENOMYX INC SNMX · Entity 162645 | Disposition to issuerStock Option (right to buy) · Derivative | 363,000 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001209191-18-057004 · doc4.xml · derivative · entry 4 POYHONEN JOHN · CIK 0001286100 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 363,000 shares Expires 2028-03-14 F5 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F5 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:12 UTC | SENOMYX INC SNMX · Entity 162645 | Disposition to issuerStock Option (right to buy) · Derivative | 417,000 | Not disclosed Strike: $1.02 | Not disclosed |
DisclosureSEC source: 0001209191-18-057004 · doc4.xml · derivative · entry 3 POYHONEN JOHN · CIK 0001286100 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 417,000 shares Expires 2027-03-14 F5 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F5 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:12 UTC | SENOMYX INC SNMX · Entity 162645 | OtherCommon Stock | 108,293 | $1.50 | $162,439.50 |
DisclosureSEC source: 0001209191-18-057004 · doc4.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 0 F1 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F4 · shares: Includes 25,772 shares of Common Stock that were acquired by the Reporting Person on 8/31/18 pursuant to the Issuer's Employee Stock Purchase Plan. F2 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3 · ownership.direct: Prior reports erroneously reflected all shares as indirectly held by trust, when a portion of the shares were actually directly held by the insider as reflected herein. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:12 UTC | SENOMYX INC SNMX · Entity 162645 | OtherCommon Stock | 111,469 | $1.50 | $167,203.50 |
DisclosureSEC source: 0001209191-18-057004 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3 · ownership.direct: Prior reports erroneously reflected all shares as indirectly held by trust, when a portion of the shares were actually directly held by the insider as reflected herein. Read SEC document |
| March 15, 2018 Filed Mar 21, 2018 18:52 UTC | SENOMYX INC SNMX · Entity 162645 | GrantStock option (right to buy) · Derivative | 363,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001437749-18-005186 · rdgdoc.xml · derivative · entry 2 POYHONEN JOHN · CIK 0001286100 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,000 Underlying: Common Stock · 363,000 shares Expires 2028-03-14 F2 · derivative.exercise_date: The stock option was granted on 03/15/2018. The option vests over four years with 1/4 of the total number of shares subject to the option vesting on the first anniversary of the date of grant and 1/48th of the total number of shares subject to the option vesting monthly thereafter, until fully vested on 03/15/2022. Read SEC document |
| February 28, 2018 Filed Mar 21, 2018 18:52 UTC | SENOMYX INC SNMX · Entity 162645 | GrantCommon Stock | 15,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-005186 · rdgdoc.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 193,990 F1 · price: Although not required, the Reporting Person has elected to report 15,545 shares acquired by the Reporting Person on 2/28/18 pursuant to the Issuer's Employee Stock Purchase Plan Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:18 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066634 · doc4.xml · derivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2027-12-18 F1 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| March 23, 2017 Filed Mar 23, 2017 19:04 UTC | SENOMYX INC SNMX · Entity 162645 | PurchaseCommon Stock | 15,000 | $0.99 | $14,800.50 |
DisclosureSEC source: 0001437749-17-005154 · rdgdoc.xml · nonDerivative · entry 2 POYHONEN JOHN · CIK 0001286100 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,293 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9787 to $0.9928, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (3) to this Form 4. F2 · balance_after: Of this amount, 108,293 shares of common stock are held indirectly by a trust. Read SEC document |
| March 22, 2017 Filed Mar 23, 2017 19:04 UTC | SENOMYX INC SNMX · Entity 162645 | PurchaseCommon Stock | 35,000 | $0.98 | $34,226.50 |
DisclosureSEC source: 0001437749-17-005154 · rdgdoc.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,293 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9576 to $0.9995, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. F2 · balance_after: Of this amount, 108,293 shares of common stock are held indirectly by a trust. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 16:51 UTC | SENOMYX INC SNMX · Entity 162645 | GrantStock option (right to buy) · Derivative | 417,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001437749-17-004848 · rdgdoc.xml · derivative · entry 2 POYHONEN JOHN · CIK 0001286100 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,000 Underlying: Common Stock · 417,000 shares Expires 2027-03-14 F2 · derivative.exercise_date: The stock option was granted on 03/15/2017. The option vests over four years with 1/4 of the total number of shares subject to the option vesting on the first anniversary of the date of grant and 1/48th of the total number of shares subject to the option vesting monthly thereafter, until fully vested on 03/15/2021. Read SEC document |
| February 28, 2017 Filed Mar 17, 2017 16:51 UTC | SENOMYX INC SNMX · Entity 162645 | GrantCommon Stock | 7,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-17-004848 · rdgdoc.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 108,293 F1 · price: Although not required, the Reporting Person has elected to report 7,990 shares acquired by the Reporting Person on 2/28/17 pursuant to the Issuer's Employee Stock Purchase Plan Read SEC document |
| January 19, 2017 Filed Jan 23, 2017 21:29 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | PurchaseCommon Stock | 10,000 | $12.20 | $122,000.00 |
DisclosureSEC source: 0001209191-17-005086 · doc4.xml · nonDerivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 21:07 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156665 · doc4.xml · derivative · entry 1 POYHONEN JOHN · CIK 0001286100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2026-12-21 F1 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.